INTRODUCTION
Impaired nutrient homeostasis is a common characteristic of metabolic disorders, such as obesity, diabetes, cardiovascular diseases and fatty liver disease. Nutrient homeostasis is tightly regulated through the balance between energy-producing pathways, such as ketogenesis, gluconeogenesis and lipid synthesis, and energy utilization pathways, such as lipid oxidation. Because of the emerging epidemic of obesity and diabetes, the factors determining progression of non-alcoholic fatty liver disease (NAFLD) present a major clinical challenge. In particular, fatty liver can progress to non-alcoholic steatohepatitis (NASH) after overwhelming of the adaptive mechanisms that mediate lipid partitioning and metabolism, and protect hepatocytes from lipotoxicity of excess fatty acids (FAs) and other lipids, resulting in inflammation and fibrosis.
Peroxisome proliferative-activated receptors (PPARs) are members of the nuclear receptor superfamily, and include PPARa, PPARb/d and PPARc. On ligand binding, PPARs form heterodimers with the retinoid X receptor, and interact with PPAR response elements to regulate target gene expression. PPARa is most prominently expressed in the liver, and is activated by hypolipidemic fibrate-class drugs (fibrates). PPARa controls lipid flux in the liver by modulating FA transport and b-oxidation, and improves plasma lipid profiles by decreasing triglyceride (TG) levels and increasing high-density lipoprotein cholesterol levels. In addition, PPARa activation inhibits inflammatory genes that are induced by nuclear factor-jB, and decreases the expression of acute-phase response genes. Accordingly, PPARa deficiency increases susceptibility to NAFLD, NASH, hepatic inflammation and acute phase responses 1 .
Fibrates, such as gemfibrozil, bezafibrate, and fenofibrate (Feno), decrease plasma TG levels, and increase high-density lipoprotein cholesterol levels in patients with hyperlipidemia and type 2 diabetes, and can prevent coronary heart disease and stroke [2] [3] [4] [5] [6] . However, these drugs are weak agonists of PPARa, have poor substrate selectivity and require high clinical doses. Therefore, a potent and selective PPARa agonist is required for patients with metabolic syndrome. K-877 is a novel selective PPARa modulator (SPPARMa) that enhances PPARa activity 7 ; it also elicits higher PPARa activation than other fibrates, with lower EC 50 values and higher PPAR subtype selectivity 8 .
In the present study, we compared the effects of K-877 on lipid metabolism and hepatic gene expression related to NASH/ NAFLD with the classical PPARa agonists, Feno and Wy14643 (Wy), in vitro and in vivo.
MATERIALS AND METHODS
Reagents K-877 was kindly provided by Kowa Co. Ltd. Feno and Wy were purchased from Sigma-Aldrich (St. Louis, Missouri, USA).
Animals
Eight-week-old male C57BL/6J (wild-type; WT) mice were obtained from CLEA Japan (Tokyo, Japan). B6;129S4-Ppara tm1Gonz/J (Ppara -/-) mice were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). Methionine-cholinedeficient (MCD)-diet analyses were carried out on 8-week-old male mice that were fed for 4 weeks and killed without fasting. All animal husbandry procedures and experiments were compliant with the University of Tsukuba's Regulations for Animal Experiments, and were approved by the Animal Experiment Committee at the University of Tsukuba.
Histological analysis
Harvested livers were fixed, embedded in paraffin, sectioned and stained with hematoxylin-eosin.
Plasmids
The expression vector for the Gal4-PPARa (pM Gal4-PPARa) fusion protein was generated by inserting a human PPARa fragment (166-468 aa) downstream of Gal4 in the pM vector (Clontech, Palo Alto, California, USA). The GAL4 UAS-LUC vector contains eight copies of the UAS Gal4-binding site 9 .
Cell culture Mouse AML12.2 hepatoma cells were maintained in Dulbecco's modified Eagle's medium/Ham's F12 media supplemented with ITS Liquid Media Supplement (Sigma-Aldrich), 100 U/mL penicillin, 100 lg/mL streptomycin and 10% fetal bovine serum. Cells were incubated with Feno (50 lmol/L) or K-877 (5 and 50 lmol/L) for 48 h.
Transfections and Luc assays
HepG2 cells were grown at 37°C in an atmosphere of 5% CO 2 in Dulbecco's modified Eagle's medium containing 25 mmol/L glucose, 100 U/mL penicillin, 100 lg/mL streptomycin and 10% fetal bovine serum. Transfection studies were carried out in cells on 24-well plates. Cells were transfected with pM Gal4-PPARa DBD and GAL4 UAS luciferase vectors 9 , and a pRL-SV40 plasmid as a reference (Promega, Madison, Wisconsin, USA) using X-tremeGENE 9 (Roche, Basel, Switzerland). After 24 h of transfection, Wy (50 lmol/L), Feno (30 lmol/L) or K-877 (50 nmol/L) were added to the medium. After additional 24-h incubation, firefly luciferase activity was measured and normalized to that of Renilla.
Metabolic measurements
Plasma levels of TG, non-esterified FA (NEFA), total cholesterol (TC), aspartate aminotransferase, alanine aminotransferase, and liver TG and TC levels were measured as described previously 10 .
Analysis of gene expression
Total ribonucleic acid from cells and tissues was prepared using a Trizol reagent (Invitrogen, Carlsbad, California, USA). Before real-time polymerase chain reaction analyses, total ribonucleic acid was reversed transcribed into complementary deoxyribonucleic acid using a reverse transcriptase according to the manufacturer's instructions (Invitrogen). Real-time polymerase chain reaction was carried out using an ABI Prism 7300 system (ABI, Carlsbad, California, USA) with TaqMan probes (Invitrogen) and a SYBR Green Master Mix (Roche) 11 . Primer sequences are available on request.
Statistical analysis
Comparisons of treatment groups were made using Tukey-Kramer post-hoc tests, and differences were considered significant and tended to reduce TC and NEFA levels (Figure 2a) , and the effects of both agonists were blunted in Ppara -/-mice (Figure 2a) . These data show that considering the concentrations of agonists, K-877 elicits greater PPARa-mediated lipid-lowering effects than Feno. Accordingly, hepatic gene expression of Ppara and its target genes, such as those encoding cyclic adenosine monophosphate responsive element binding protein 3-like 3 (Creb3l3), Fgf21, acyl-CoA oxidase 1, palmitoyl (Acox1) and carnitine palmitoyltransferase 1a, liver (Cpt1a), were significantly increased by both PPARa agonists (Figure 2b ). These changes in gene expression were similar in the presence of K-877 and Feno despite dose differences, showing that K-877 has more powerful effects on PPARa activation than Feno. In addition, the effects of both agonists were abolished in Ppara -/-mice, confirming that these agonists target the PPARa pathway.
K-877 suppresses MCD-induced liver injury in normal mice, but not in Ppara -/-mice To compare the effects of PPARa agonists on the progression of NAFLD, WT and Ppara -/-mice were fed an MCD diet containing 0.1% Feno or 0.00025% K-877 for 4 weeks, and their optimum doses were determined according to previously reported methods 7, 12 . This diet has been used extensively to produce diet-induced animal models of NASH that show similar histology to that of human NASH 1 . Histological analyses of hematoxylin-eosin-stained liver sections from WT mice showed that the MCD diet led to slight lipid accumulation in hepatocytes (Figure 3a) . The addition of Feno and K-877 suppressed MCD-induced lipid accumulation (Figure 3a) . Furthermore, sections from MCD-fed Ppara -/-mice showed greater lipid accumulation and macrophage invasion than those from MCD-fed WT mice, but the addition of Feno and K-877 could not improve them (Figure 3a) . Hepatic TG and TC contents were significantly increased in MCD diet-fed mice than in MF diet-fed mice (Figure 3b ). The addition of K-877 and Feno into MCD diets tended to reduce liver TG and TC levels, and Ppara -/-mice showed more severe liver lipid accumulation than WT mice (Figure 3b ). However, PPARa agonists did not improve these phenotypes significantly (Figure 3b) . In further analyses, increased plasma alanine aminotransferase and aspartate aminotransferase levels were observed in MCD diet-fed WT mice, compared with those in MF diet-fed WT mice (Figure 3c) . The administration of K-877 or Feno tended to decrease MCD diet-induced alanine aminotransferase and aspartate aminotransferase levels. However, both agonists failed to suppress these increases in Ppara -/-mice (Figure 3c ). Taken together, these data suggest that K-877 and Feno ameliorate MCD diet-induced fatty liver progression.
K-877 activates PPARa target gene expression and reduces
Xbp1s expression in the liver of MCD-fed mice Hepatic gene expression was determined in WT and Ppara -/-mice after feeding on a MCD diet containing PPARa agonists for 4 weeks. Consistent with the expression levels of Ppara and its target genes Creb3l3 in normal mice, Acox1 and Cpt1a were significantly increased to similar levels in the presence of PPARa agonists (Figure 4) . However, Fgf21 expression was decreased in the presence of PPARa agonists. Furthermore, no apparent differences in inflammatory and macrophage hepatic gene expression were observed between MCD diet-fed WT mouse groups. The administration of PPARa agonists on Ppara -/-mice showed increased Cd68 expression, supporting the increase of macrophages including Kupffer cells. However, the MCD diet induced endoplasmic reticulum (ER) stress markers, such as X-box binding protein 1s (Xbp1s) in WT mice. In addition, the effects of K-877 on Xbp1s expression were abolished in Ppara -/-mice. In subsequent experiments, K-877 suppressed MCD diet-induced Xbp1s expression more efficiently than Feno, thereby ameliorating ER stress in MCD diet-fed WT mice. In contrast, neither PPARa agonist suppressed ER stress-related gene expression in Ppara -/-mice. These data show that K-877 increases PPARa target genes that are related to FA oxidation and reduces Xbp1s expression, leading to decreased liver injury.
DISCUSSION
In the present study, we showed that K-877 specifically and efficiently activates PPARa transactivation activity in vitro and mice. Eight-week-old male WT and Ppara -/-mice were fed moderate-fat (MF) or MCD diets containing fenofibrate (Feno; 0.1%) or K-877 (0.00025%) for 4 weeks. Hematoxylin-eosin staining in the (a) liver, (b) hepatic lipid contents, and (c) plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were determined in WT and Ppara -/-mice; n = 5-10 per group, *P < 0.05 and **P < 0.01. TC, total cholesterol; TG, triglyceride. in vivo. Furthermore, K-877 had greater lipid-lowering effects than the classical PPARa agonists in mice, and significantly induced PPARa target genes. These effects reduced MCDinduced liver injury by increasing PPARa target gene expression and decreasing ER stress in the liver. Therefore, K-877 might be an effective drug for hyperlipidemia.
450
Fibrates are widely used to ameliorate the macro-and microvascular risks associated with metabolic syndrome. However, these agents are weak PPARa agonists, and have limited efficacy due to dose-related adverse events. To address this problem, a new generation of PPARa-specific agonists, known as SPPARMas, has been developed to maximize receptormediated effects and diminish side effects. In luciferase analyses, we confirmed that K-877 activates PPARa at 1,000-fold lower doses than Feno and Wy. K-877 increases Fgf21 expression, one of the typical target genes for PPARa in AML12.2 cells. FGF21 is known to ameliorate obesity, diabetes and hyperlipidemia by inducing lipid catabolism 13, 14 . The in vivo studies showed that K-877 and Feno induced the PPARa target genes, Fgf21, Acox1 and Cpt1a, in the liver of MF-fed WT mice, suggesting that these compounds activate hepatic FA oxidation. These effects were similar in the presence of low doses of K-877, or high doses of Feno, suggesting superiority of K-877 as a clinical agent. As a result, the administration of K-877 and Feno in MFfed WT mice reduced plasma lipids, including TG, TC and NEFA. Previous reports have shown that some PPARa agonists prevent the progression of NAFLD 15, 16 . Accordingly, K-877 efficiently increased the PPARa transcriptional activity and subsequently transactivated FA oxidation genes, including Acox1 and Cpt1a, resulting in reduced hepatic lipid accumulation in MCDfed mice. However, Fgf21 expression was decreased in MCD-fed WT mice in the presence of PPARa agonist compared with that in MCD-fed WT mice without agonists. Fgf21 expression was induced in both WT and Ppara -/-mice in response to MCD, suggesting that a PPARa independent mechanism underlies MCD-induced Fgf21 expression. 
